ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0337

Impact of Photosensitivity on Quality of Life in Dermatomyositis

Kirubel Gebre1, Rachita Pandya2, Julianne Kleitsch2, Darosa Lim3, Rui Feng3 and victoria werth4, 1Perelman School of Medicine at the University of Pennsylvania, Lancaster, PA, 2Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA, 4University of Pennsylvania, Wynnewood, PA

Meeting: ACR Convergence 2023

Keywords: dermatomyositis, Patient reported outcomes, quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0325–0344) Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Photosensitivity (PS) has been documented in dermatomyositis (DM) with symptoms including aggravation of preexisting cutaneous lesions and abnormal transient erythemal responses (Cheong WK et al. 1994). DM has a large negative impact on quality of life (QoL), and DM skin disease activity has been correlated with poorer QoL (Goreshi R et al. 2011). Yet, the impact of PS specifically on QoL in DM has not been well studied. The aims of this study are to examine the impact of PS on QoL and to determine whether there is a relationship between PS-specific QoL measures and degree of cutaneous disease activity in DM.

Methods: Prospectively acquired data from 401 subjects with either classic DM (CDM) or clinically amyopathic DM (CADM) who completed the Skindex-29+3 was used. The Skindex-29+3 is a modified version of the Skindex-29, a validated measure of skin-specific QoL (Chren MM et al. 1997). Two of the three items added to the Skindex-29 relate to PS, items 31 and 33: “I worry about going outside because the sun might flare my disease” and “My skin disease prevents me from doing outdoor activities”. The average of these two items comprises the PS subscale. Item 32, “I am worried about my hair loss”, is the third added item in the Skindex-29+3. We compared patient responses to cutaneous disease activity using the Cutaneous Disease Area and Severity Index (CDASI), a validated tool for measuring DM disease (Ahmed S et al. 2020). Subject responses were not normally distributed, and group differences were assessed using the Wilcoxon rank-sum test. All three additional items of the Skindex-29+3 were correlated to CDASI activity scores using Spearman correlations. The three items were also correlated to the symptom, emotion, and function subscales of the Skindex-29+3 using Spearman correlations.

Results: Of 401 subjects, 52% worried “often” or “all the time” about going outside because the sun might flare their disease (Item 31). 42% of subjects reported worrying about their hair loss (Item 32) “often” or “all the time”. 39% of subjects reported being prevented from doing outdoor activities (Item 33) “often” or “all the time”. There were no significant differences in median responses for Items 31 and 32 between patients with CDM and CADM (p = 0.407, 0.239), but there was a significant difference for Item 33 (p = 0.021), with CDM subjects reporting higher scores. There was a moderate, positive correlation between the PS subscale and both the function and emotion subscales for all subjects (rs = 0.580, p < 0.001, rs = 0.527, p < 0.001). There was another moderate, positive correlation between Item 33 and both function and emotion subscales (rs = 0.611, p < 0.001, rs = 0.516, p < 0.001). We found a negligible correlation for Items 31, 32, 33, and the PS subscale in relation to CDASI activity scores (rs = 0.124 p = 0.013, rs = 0.249 p < 0.001, rs = 0.183 p < 0.001, rs = 0.169 p = 0.001).

Conclusion: PS in DM has a significant impact on QoL in CDM and CADM. Concern regarding hair loss is common among subjects with DM. Subjects with CDM experienced greater limitation in participating in outdoor activities when compared to subjects with CADM (p = 0.021). Subjects that experienced greater PS-related concerns and limitations had greater emotional burden and functional impairments.

Supporting image 1

Figure 1. Percent of subject responses to Item 31 by DM subtype

Supporting image 2

Figure 2. Percent of subject responses to Item 32 by DM subtype

Supporting image 3

Figure 3. Percent of subject responses to Item 33 by DM subtype. There was a significant difference in the median responses between subjects with classic DM (CDM) and clinically amyopathic DM (CADM), with CDM subjects reporting higher scores (p = 0.021).


Disclosures: K. Gebre: None; R. Pandya: None; J. Kleitsch: None; D. Lim: None; R. Feng: None; v. werth: AbbVie, 2, Amgen, 2, 5, Argenx, 2, AstraZeneca, 2, 5, Beacon Bioscience, 2, Biogen, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, Celgene, 2, 5, Corcept, 2, Crisalis, 2, CSL Behring, 2, Cugene, 2, Eli Lilly, 2, EMD Serono, 2, Genentech, 2, Gilead, 2, 5, GlaxoSmithKline, 2, Idera, 2, Incyte, 2, Janssen, 2, 5, Kirin, 2, Lupus Research Alliance, 5, MedImmune, 2, Medscape, 2, Nektar, 2, Principia, 2, Resolve, 2, UCB, 2, Viela Bio, 2, 5.

To cite this abstract in AMA style:

Gebre K, Pandya R, Kleitsch J, Lim D, Feng R, werth v. Impact of Photosensitivity on Quality of Life in Dermatomyositis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/impact-of-photosensitivity-on-quality-of-life-in-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-photosensitivity-on-quality-of-life-in-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology